格隆汇1月16日丨华熙生物(688363.SH)公布，截至2026年1月15日，国寿成达以集中竞价方式减持公司 股份481.68万股，以大宗交易方式减持公司股份481.68万股，合计减持公司股份963.36万股，减持计划 已实施完毕。 ...

Market Overview - The medical beauty sector experienced a decline of 1.79% on January 16, with Huaxi Biological leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] Individual Stock Performance - Jinbo Biological (920982) closed at 235.00, with a slight increase of 0.38% and a trading volume of 6758.42 lots [1] - ST Meigu (000615) closed at 3.43, up 0.29% with a trading volume of 12.66 million [1] - Aimeike (300896) closed at 146.31, down 1.68% with a trading volume of 35,000 [1] - Huaxi Biological (688363) closed at 46.31, down 2.24% with a trading volume of 51,600 [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 112 million yuan from main funds, while retail investors contributed a net inflow of 73.41 million yuan [1] - The detailed capital flow for individual stocks shows: - ST Meigu had a main fund net outflow of 446,500 yuan and a retail net inflow of 198,200 yuan [2] - Jinbo Biological experienced a main fund net outflow of 7.88 million yuan and a retail net outflow of 223,700 yuan [2] - Huaxi Biological had a significant main fund net outflow of 46.59 million yuan, with retail investors contributing a net inflow of 27.27 million yuan [2] - Aimeike faced a main fund net outflow of 64.99 million yuan, while retail investors had a net inflow of 45.95 million yuan [2]

直面"死亡之谷"：科技成果转化的中国困境与破局关键 在生物制造领域，"死亡之谷"是业界对科研成果从实验室走向市场应用过程中，一道难以逾越的产业化 鸿沟的形象比喻。 日前，工业和信息化部首批《生物制造中试能力建设平台名单》公示落下帷幕。在这场关乎国家未来产 业竞争力的权威评选中，华熙生物科技（天津）有限公司凭借全球规模领先的合成生物中试平台脱颖而 出，不仅成功入选，更获评最高"五星"等级。尤为引人注目的是，该公司在化妆品、食品添加剂、生物 制药三大核心领域同时斩获最高认证，成为全国仅有的5家五星单位之一。 这枚"五星"认证，不仅是对一家企业技术实力的肯定，更让长期隐身于产业幕后的"中试平台"这一生物 制造领域的关键基础设施进入公众视野。在我国科技成果转化率仅约10%的产业背景下，这座平台为何 能成为跨越科研与产业化"死亡之谷"的核心力量？ 天津中合基因科技有限公司的案例极具说服力。该公司一项关于"关键酶"的研发在完成实验室小试后， 因无力承担上千万元的中试线建设成本而陷入停滞。入驻华熙生物中试转化平台后，仅用一个月便完成 了工艺放大测试，成本较自建缩减了90%，成功跨越了产业化的最关键一道坎。 超越企业边界：构 ...

Core Viewpoint - Huaxi Biological experienced a stock price decline of 2.01% on January 16, with a trading price of 46.42 yuan per share and a total market capitalization of 22.36 billion yuan [1] Group 1: Stock Performance - Since the beginning of the year, Huaxi Biological's stock price has increased by 6.27%, with a 0.41% rise over the last five trading days and a 6.10% increase over the last 20 days, while it has decreased by 13.56% over the last 60 days [2] - As of November 20, the number of shareholders for Huaxi Biological is 30,100, a decrease of 0.62% from the previous period, with an average of 16,014 circulating shares per person, which is an increase of 0.62% [2] Group 2: Financial Performance - For the period from January to September 2025, Huaxi Biological reported a revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2] - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3] Group 3: Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Huaxi Biological include several ETFs, with notable reductions in holdings: E Fund's Shanghai Stock Exchange Science and Technology Innovation Board 50 ETF decreased by 1.0136 million shares, while Huaxia's ETF decreased by 0.38234 million shares [3] - Other significant shareholders also saw reductions, including Hong Kong Central Clearing Limited, which decreased its holdings by 0.31229 million shares [3]

华熙生物1月15日大宗交易平台出现一笔成交，成交量65.00万股，成交金额2830.75万元，大宗交易成交 价为43.55元，相对今日收盘价折价8.06%。该笔交易的买方营业部为机构专用，卖方营业部为中国国际 金融股份有限公司北京建国门外大街证券营业部。 进一步统计，近3个月内该股累计发生51笔大宗交易，合计成交金额为2.04亿元。 据天眼查APP显示，华熙生物科技股份有限公司成立于2000年01月03日，注册资本48167.8242万人民 币。（数据宝） 1月15日华熙生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | 业部 | | | 65.00 | 2830.75 | 43.55 | -8.06 | 机构专 | 中国国际金融股份有限公司北京建国 | | | | | | 用 | 门外大街证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，华熙生物今日收盘价为47.37元，下跌0.17%，日换手率为0 ...

进一步统计，近3个月内该股累计发生51笔大宗交易，合计成交金额为2.04亿元。该股近5个交易日累计 上涨5.01%，主力资金合计净流入6637万元。 责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 1月15日，华熙生物收跌0.17%，收盘价为47.37元，发生1笔大宗交易，合计成交量65万股，成交金额 2830.75万元。 第1笔成交价格为43.55元，成交65.00万股，成交金额2,830.75万元，溢价率为-8.06%，买方营业部为机 构专用，卖方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部。 ...

| 胶景垫五信息 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | 2026-01-15 | 华熙生物 | 688363 | 43.55 2830.75 | . 65 | 机构专用 | 視點難 | | 190 | 1月15日，华熙生物大宗交易成交65万股，成交额2830.75万元，占当日总成交额的11.84%，成交价 43.55元，较市场收盘价47.37元折价8.06%。 ...

Core Viewpoint - The documentary "拾光" produced by Huaxi Biological and "Great National Brands" showcases the journey of Huaxi Biological from breaking through the technical barriers of hyaluronic acid to creating a complete synthetic biology ecosystem, reflecting the evolution of China's biotechnology industry from following to leading [1][21]. Group 1: Historical Context and Technological Breakthroughs - In 1934, American scientists first isolated hyaluronic acid from bovine vitreous body, and by the 1970s, Western countries had industrialized it through extraction from chicken combs, but faced limitations in extraction efficiency and high costs, restricting its application to high-value fields like medicine and cosmetics [3]. - In 2000, Huaxi Biological initiated independent research and development of hyaluronic acid, successfully achieving large-scale production through microbial fermentation, breaking foreign technical barriers and significantly reducing costs, making hyaluronic acid more accessible [5]. Group 2: Research and Development Achievements - As of June 30, 2025, Huaxi Biological has applied for 1,081 patents, including 855 invention patents, establishing a comprehensive R&D capability from gene editing to large-scale fermentation [5]. - The company has undergone systematic upgrades of hyaluronic acid technology, achieving significant milestones such as large-scale production via microbial fermentation, the global first "enzyme-cutting method" for producing oligo-hyaluronic acid, and the establishment of a synthetic biology platform [8][10]. Group 3: Market Applications and Brand Development - Huaxi Biological has expanded the applications of hyaluronic acid from the medical field to food, skincare, reproductive health, and textiles, broadening the industry's prospects [10]. - The company has built a global R&D network with top institutions like Tsinghua University and Harvard University, and invested over 3 billion yuan in a leading synthetic biology pilot transformation platform [10]. Group 4: Innovation Ecosystem and Commercial Success - Huaxi Biological's complete innovation system, from basic research to large-scale production, allows it to bridge the gap in technology commercialization, exemplified by the success of its product "润百颜" which has sold hundreds of millions of units globally [11]. - The company has developed a range of brands covering health, beauty, and quality of life, demonstrating the tangible impact of technology on consumers' lives [15]. Group 5: Cultural and Social Contributions - Huaxi Biological actively contributes to cultural and sports vitality in Chinese cities through investments in landmark projects and cultural commercial ecosystems [17]. - The "Cloud Public Welfare" project has reached 19 provinces and 43 ethnic minority areas, supporting intangible cultural heritage projects and donating medical equipment to rural schools [19].

华熙生物获五星认证，彰显国家生物制造产业战略布局。2025年6月，工信部与发改委联合发文，明确 2027年培育20个以上中试平台，打通成果转化链条。生物制造是全球产业竞争焦点，预计2030年全球市 场规模超3900亿美元，我国布局质量关乎全球话语权。 该平台以"行业级基础设施"定位开放共享，通过多元模式为高校、科研院所等提供全链条服务，推 动"政产学研金服用"融合。天津相关政策鼓励中试平台建设，2024年当地生物医药产业增加值增长 8.7%，188个在建项目总投资超535亿元，形成良性产业生态。 数据显示，我国科技成果转化率仅约10%，远低于欧美发达国家75%的转化率水平，大量科研成果止步 实验室，形成科研与产业化"死亡之谷"。在生物制造领域，实验室可通过基因编辑构建"细胞工厂"实现 毫克级、克级目标物质制备，但向数万升发酵罐规模化生产转化时，任一参数偏差都可能导致"细胞工 厂"失效，引发生产线的亏损。 华熙生物董事长赵燕指出，中试是跨越"死亡之谷"的关键，无中试则生物技术难以产业化。作为小试与 大生产的过渡，中试核心是攻克工艺放大难题，将实验室成果规模化放大，完成工艺优化、质量控制等 前置准备，形成工业生产 ...

Core Viewpoint - The 2025 China Enterprise ESG "Golden Responsibility Award" aims to recognize companies and institutions that have made significant contributions to ESG initiatives in China, reflecting a shift from voluntary practices to compliance requirements in ESG performance [1][12]. Group 1: ESG Development and Awards Overview - By 2025, China's ESG development has transitioned from "setting standards" to "strengthening regulations," with a comprehensive disclosure standard system being established [1][12]. - The award selection attracted over 5,000 companies, with results based on ESG performance, online voting, and professional evaluations [2][12]. Group 2: Award Categories and Winners - The award categories include Excellent Environmental Responsibility Award, Excellent Social Responsibility Award, Excellent Corporate Governance Responsibility Award, Excellent Responsibility Initiative Award, Excellent Sustainable Development Award, and various responsibility investment awards [1][12]. - Notable winners of the Excellent Environmental Responsibility Award include Great Wall Motors, Hikvision, and China Petroleum [7][24]. - The Excellent Social Responsibility Award was awarded to companies such as YF Communication, ZTE, and Ningde Times [7][24]. - Winners of the Excellent Corporate Governance Responsibility Award include China Petroleum, Hikvision, and WuXi AppTec [7][24]. - The Excellent Responsibility Initiative Award was given to companies like ZTE, Sunlight Power, and Industrial and Commercial Bank of China [7][24]. - The Excellent Sustainable Development Award included companies such as WanHua Chemical, China Bank, and China Petroleum [7][24]. Group 3: Responsibility Investment Awards - The Responsibility Investment Excellent Bank Award was given to institutions like CITIC Bank and Minsheng Bank [5][21]. - The Responsibility Investment Excellent Securities Company Award included firms such as Shenwan Hongyuan and CITIC Securities [5][22]. - The Responsibility Investment Excellent Insurance Company Award recognized companies like New China Life and AIA [5][26]. - The Responsibility Investment Excellent Fund Company Award included firms such as Xinhua Fund and Harvest Fund [5][27]. - The Responsibility Investment Excellent Asset Management Institution Award recognized institutions like Ping An Asset Management and Sunshine Asset Management [5][28]. Group 4: Call to Action and Future Directions - The award committee encourages more Chinese enterprises to integrate ESG principles into their operations and strategic planning, emphasizing the importance of balancing commercial and social values [10][29].